

RECEIVED

JUN 04 2003

TECH CENTER 1600 2003

1600

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/724,567

DATE: 05/27/2003

TIME: 09:04:18

Input Set : A:\015270-005911US.APP

Output Set: N:\CRF4\05272003\I724567.raw

3 <110> APPLICANT: Schenk, Dale B.
 4 Elan Pharmaceuticals
 6 <120> TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Diseases
 8 <130> FILE REFERENCE: 015270-005911US
 10 <140> CURRENT APPLICATION NUMBER: US 09/724,567
 11 <141> CURRENT FILING DATE: 2000-11-28
 13 <150> PRIOR APPLICATION NUMBER: WO PCT/US00/25239
 14 <151> PRIOR FILING DATE: 2000-06-01
 16 <150> PRIOR APPLICATION NUMBER: US 60/137,010
 17 <151> PRIOR FILING DATE: 1999-06-01
 19 <160> NUMBER OF SEQ ID NOS: 34
 21 <170> SOFTWARE: PatentIn Ver. 2.1
 23 <210> SEQ ID NO: 1
 24 <211> LENGTH: 13
 25 <212> TYPE: PRT
 26 <213> ORGANISM: Artificial Sequence
 28 <220> FEATURE:
 29 <223> OTHER INFORMATION: Description of Artificial Sequence:influenza
 30 hemagglutinin HA 307-319 universal T-cell epitope
 32 <400> SEQUENCE: 1
 33 Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr
 34 1 5 10
 37 <210> SEQ ID NO: 2
 38 <211> LENGTH: 13
 39 <212> TYPE: PRT
 40 <213> ORGANISM: Artificial Sequence
 42 <220> FEATURE:
 43 <223> OTHER INFORMATION: Description of Artificial Sequence:PADRE universal
 44 T-cell epitope
 46 <220> FEATURE:
 47 <221> NAME/KEY: MOD_RES
 48 <222> LOCATION: (3)
 49 <223> OTHER INFORMATION: Xaa = any amino acid
 51 <400> SEQUENCE: 2
 W--> 52 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala
 53 1 5 10
 56 <210> SEQ ID NO: 3
 57 <211> LENGTH: 16
 58 <212> TYPE: PRT
 59 <213> ORGANISM: Artificial Sequence
 61 <220> FEATURE:
 62 <223> OTHER INFORMATION: Description of Artificial Sequence:malaria CS T3
 63 epitope universal T-cell epitope

P.6

ENTERED

RAW SEQUENCE LISTING DATE: 05/27/2003
PATENT APPLICATION: US/09/724,567 TIME: 09:04:18

Input Set : A:\015270-005911US.APP
Output Set: N:\CRF4\05272003\I724567.raw

65 <400> SEQUENCE: 3
66 Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn Val
67 1 5 10 15
70 <210> SEQ ID NO: 4
71 <211> LENGTH: 10
72 <212> TYPE: PRT
73 <213> ORGANISM: Artificial Sequence
75 <220> FEATURE:
76 <223> OTHER INFORMATION: Description of Artificial Sequence:Hepatitis B
77 surface antigen HBsAg 19-28 universal T-cell
78 epitope
80 <400> SEQUENCE: 4
81 Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile
82 1 5 10
85 <210> SEQ ID NO: 5
86 <211> LENGTH: 19
87 <212> TYPE: PRT
88 <213> ORGANISM: Artificial Sequence
90 <220> FEATURE:
91 <223> OTHER INFORMATION: Description of Artificial Sequence:heat shock
92 protein 65 hsp65 153-171 universal T-cell epitope
94 <400> SEQUENCE: 5
95 Asp Gln Ser Ile Gly Asp Leu Ile Ala Glu Ala Met Asp Lys Val Gly
96 1 5 10 15
98 Asn Glu Gly
102 <210> SEQ ID NO: 6
103 <211> LENGTH: 14
104 <212> TYPE: PRT
105 <213> ORGANISM: Artificial Sequence
107 <220> FEATURE:
108 <223> OTHER INFORMATION: Description of Artificial Sequence:bacillus
109 Calmette-Guerin universal T-cell epitope
111 <400> SEQUENCE: 6
112 Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu
113 1 5 10
116 <210> SEQ ID NO: 7
117 <211> LENGTH: 15
118 <212> TYPE: PRT
119 <213> ORGANISM: Artificial Sequence
121 <220> FEATURE:
122 <223> OTHER INFORMATION: Description of Artificial Sequence:tetanus toxoid
123 TT 830-844 universal T-cell epitope
125 <400> SEQUENCE: 7
126 Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu
127 1 5 10 15
130 <210> SEQ ID NO: 8
131 <211> LENGTH: 21
132 <212> TYPE: PRT
133 <213> ORGANISM: Artificial Sequence

RAW SEQUENCE LISTING DATE: 05/27/2003
PATENT APPLICATION: US/09/724,567 TIME: 09:04:18

Input Set : A:\015270-005911US.APP
Output Set: N:\CRF4\05272003\I724567.raw

135 <220> FEATURE:
136 <223> OTHER INFORMATION: Description of Artificial Sequence:tetanus toxoid
137 TT 947-967 universal T-cell epitope
139 <400> SEQUENCE: 8
140 Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser
141 1 5 10 15
143 Ala Ser His Leu Glu
144 20
147 <210> SEQ ID NO: 9
148 <211> LENGTH: 16
149 <212> TYPE: PRT
150 <213> ORGANISM: Artificial Sequence
152 <220> FEATURE:
153 <223> OTHER INFORMATION: Description of Artificial Sequence:HIV gp120 T1
154 universal T-cell epitope
156 <400> SEQUENCE: 9
157 Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala
158 1 5 10 15
161 <210> SEQ ID NO: 10
162 <211> LENGTH: 22
163 <212> TYPE: PRT
164 <213> ORGANISM: Artificial Sequence
166 <220> FEATURE:
167 <223> OTHER INFORMATION: Description of Artificial Sequence:AN90549 (Abeta
168 1-7/tetanus toxoid 830-844 in a MAP4
169 configuration)
171 <400> SEQUENCE: 10
172 Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe
173 1 5 10 15
175 Ile Gly Ile Thr Glu Leu
176 20
179 <210> SEQ ID NO: 11
180 <211> LENGTH: 28
181 <212> TYPE: PRT
182 <213> ORGANISM: Artificial Sequence
184 <220> FEATURE:
185 <223> OTHER INFORMATION: Description of Artificial Sequence:AN90550 (Abeta
186 1-7/tetanus toxoid 947-967 in a MAP4
187 configuration)
189 <400> SEQUENCE: 11
190 Asp Ala Glu Phe Arg His Asp Phe Asn Asn Phe Thr Val Ser Phe Trp
191 1 5 10 15
193 Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu
194 20 25
197 <210> SEQ ID NO: 12
198 <211> LENGTH: 43
199 <212> TYPE: PRT
200 <213> ORGANISM: Artificial Sequence
202 <220> FEATURE:

RAW SEQUENCE LISTING DATE: 05/27/2003
PATENT APPLICATION: US/09/724,567 TIME: 09:04:18

Input Set : A:\015270-005911US.APP
Output Set: N:\CRF4\05272003\I724567.raw

203 <223> OTHER INFORMATION: Description of Artificial Sequence:AN 90542 (Abeta
204 1-7/tetanus toxoid 830-844 + 947-967 in a linear
205 configuration)
207 <400> SEQUENCE: 12
208 Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe
209 1 5 10 15
211 Ile Gly Ile Thr Glu Leu Phe Asn Asn Phe Thr Val Ser Phe Trp Leu
212 20 25 30
214 Arg Val Pro Lys Val Ser Ala Ser His Leu Glu
215 35 40
218 <210> SEQ ID NO: 13
219 <211> LENGTH: 22
220 <212> TYPE: PRT
221 <213> ORGANISM: Artificial Sequence
223 <220> FEATURE:
224 <223> OTHER INFORMATION: Description of Artificial Sequence:AN 90576 (Abeta
225 3-9/tetanus toxoid 830-844 in a MAP4
226 configuration)
228 <400> SEQUENCE: 13
229 Glu Phe Arg His Asp Ser Gly Gln Tyr Ile Lys Ala Asn Ser Lys Phe
230 1 5 10 15
232 Ile Gly Ile Thr Glu Leu
233 20
236 <210> SEQ ID NO: 14
237 <211> LENGTH: 20
238 <212> TYPE: PRT
239 <213> ORGANISM: Artificial Sequence
241 <220> FEATURE:
242 <223> OTHER INFORMATION: Description of Artificial Sequence:AN90562 (Abeta
243 1-7/peptide on linear conformation)
245 <220> FEATURE:
246 <221> NAME/KEY: MOD_RES
247 <222> LOCATION: (3)
248 <223> OTHER INFORMATION: Xaa = any amino acid
250 <400> SEQUENCE: 14
W--> 251 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asp Ala Glu
252 1 5 10 15
254 Phe Arg His Asp
255 20
258 <210> SEQ ID NO: 15
259 <211> LENGTH: 34
260 <212> TYPE: PRT
261 <213> ORGANISM: Artificial Sequence
263 <220> FEATURE:
264 <223> OTHER INFORMATION: Description of Artificial Sequence:AN90543 (Abeta
265 1-7 X 3/peptide in linear conformation)
267 <220> FEATURE:
268 <221> NAME/KEY: MOD_RES
269 <222> LOCATION: (24)

RAW SEQUENCE LISTING DATE: 05/27/2003
PATENT APPLICATION: US/09/724,567 TIME: 09:04:18

Input Set : A:\015270-005911US.APP
Output Set: N:\CRF4\05272003\I724567.raw

270 <223> OTHER INFORMATION: Xaa = any amino acid
272 <400> SEQUENCE: 15
273 Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala
274 1 5 10 15
W--> 276 Glu Phe Arg His Asp Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala
277 20 25 30
279 Ala Ala
283 <210> SEQ ID NO: 16
284 <211> LENGTH: 34
285 <212> TYPE: PRT
286 <213> ORGANISM: Artificial Sequence
288 <220> FEATURE:
289 <223> OTHER INFORMATION: Description of Artificial Sequence:fusion protein
290 with Abeta immunogenic epitope
292 <220> FEATURE:
293 <221> NAME/KEY: MOD_RES
294 <222> LOCATION: (3)
295 <223> OTHER INFORMATION: Xaa = any amino acid
297 <400> SEQUENCE: 16
W--> 298 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asp Ala Glu
299 1 5 10 15
301 Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg
302 20 25 30
304 His Asp
308 <210> SEQ ID NO: 17
309 <211> LENGTH: 20
310 <212> TYPE: PRT
311 <213> ORGANISM: Artificial Sequence
313 <220> FEATURE:
314 <223> OTHER INFORMATION: Description of Artificial Sequence:fusion protein
315 with Abeta immunogenic epitope
317 <220> FEATURE:
318 <221> NAME/KEY: MOD_RES
319 <222> LOCATION: (10)
320 <223> OTHER INFORMATION: Xaa = any amino acid
322 <400> SEQUENCE: 17
W--> 323 Asp Ala Glu Phe Arg His Asp Ala Lys Xaa Val Ala Ala Trp Thr Leu
324 1 5 10 15
326 Lys Ala Ala Ala
327 20
330 <210> SEQ ID NO: 18
331 <211> LENGTH: 24
332 <212> TYPE: PRT
333 <213> ORGANISM: Artificial Sequence
335 <220> FEATURE:
336 <223> OTHER INFORMATION: Description of Artificial Sequence:fusion protein
337 with Abeta immunogenic epitope
339 <400> SEQUENCE: 18
340 Asp Ala Glu Phe Arg His Asp Ile Ser Gln Ala Val His Ala Ala His

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/724,567

DATE: 05/27/2003
TIME: 09:04:19

Input Set : A:\015270-005911US.APP
Output Set: N:\CRF4\05272003\I724567.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:2; Xaa Pos. 3
Seq#:14; Xaa Pos. 3
Seq#:15; Xaa Pos. 24
Seq#:16; Xaa Pos. 3
Seq#:17; Xaa Pos. 10
Seq#:32; Xaa Pos. 2
Seq#:33; Xaa Pos. 1